title: Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis.
abstract: BACKGROUND
  The majority of gastro-oesophageal reflux disease (GERD) seems to be non-erosive reflux disease. Nonerosive reflux disease includes minimal change oesophagitis (whitish or reddish, oedematous change and erosion that is not regarded as mucosal break) and no endoscopic abnormalities.
  
  
  OBJECTIVE
  To investigate the accurate proportion of those with minimal change oesophagitis and to clarify its characteristics. In addition, we evaluated the effect of famotidine (40 mg/day) in those with minimal change.
  
  
  METHODS
  Prospective endoscopic assessment was performed for consecutive 606 out-patients. Of the 582 patients suitable for analysis, 347 were non-treated. The latter were divided into those with erosive GERD or minimal change, and their endoscopic findings and characteristics were compared.
  
  
  RESULTS
  Among 347 non-treated patients, 88 (25%) had erosive GERD and 249 (72%) had minimal change. Compared with patients who have erosive GERD and those with minimal change, the latter were less likely to have hiatal hernia or bile reflux, but more likely to have gastric atrophy. Symptomatic patients (n = 55) with minimal change oesophagitis were more likely to have hiatal hernia than those who were asymptomatic (n= 194). Most patients preferred taking famotidine on-demand, during a 4-week follow-up period.
  
  
  CONCLUSIONS
  Most non-erosive reflux disease can be classified as minimal change oesophagitis, and that have different characteristics from erosive GERD. On-demand famotidine may be a suitable alternative treatment for patients with minimal change disease.
authors.affiliation: Department of Endoscopy, Dokkyo University School of Medicine, Mibu, Tochigi, Japan. nakamurt@dokkyomed.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: K
authors.initials: K
authors.lastname: Shirakawa
authors.forename: H
authors.initials: H
authors.lastname: Masuyama
authors.forename: H
authors.initials: H
authors.lastname: Sugaya
authors.forename: H
authors.initials: H
authors.lastname: Hiraishi
authors.forename: A
authors.initials: A
authors.lastname: Terano
mesh_terms: D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001646:Bile / Q000737:chemistry; D003116:Color; D004941:Esophagitis / Q000175:diagnosis*; D004945:Esophagoscopy / Q000592:standards*; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D005757:Gastritis, Atrophic / Q000175:diagnosis; D005764:Gastroesophageal Reflux / Q000175:diagnosis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D000897:Anti-Ulcer Agents; D015738:Famotidine